Daftar Pustaka

1. Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S. A systematic review of asymptomatic infections. J Microbiol Immunol Infect. 2020;51(1):12–6.

2. Khan M, Adil SF, Alkhathlan HZ, Tahir MN, Saif S, Khan M, et al. COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far. Molecules. 2020;26(1):1–25.

3. Peta Sebaran COVID-19 | Covid19.go.id [Internet]. [cited 2022 Feb 4]. Available from: https://covid19.go.id/peta-sebaran-covid19

4. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data [Internet]. [cited 2022 Feb 23]. Available from: https://covid19.who.int/

5. Barranco R, Ventura F. Covid-19 and infection in health-care workers: An emerging problem. Med Leg J. 2020;88(2):65–6.

6. Song J-Y, Yun J-G, Noh J-Y, Cheong H-J, Kim W-J. Covid-19 in South Korea — Challenges of Subclinical Manifestations. N Engl J Med. 2020;382(19):1858–9.

7. Ma X, Liu S, Chen L, Zhuang L, Zhang J, Xin Y. The clinical characteristics of pediatric inpatients with SARS-CoV-2 infection: A meta-analysis and systematic review. J Med Virol [Internet]. 2021;93(1):234–40. Available from: http://dx.doi.org/10.1002/jmv.26208

8. Yuan J, Kou S, Liang Y, Zeng J, Pan Y, Liu L. Polymerase Chain Reaction Assays Reverted to Positive in 25 Discharged Patients with COVID-19. Clin Infect Dis. 2020;71(16):2230–2.

9. Wong J, Koh WC, Momin RN, Alikhan MF, Fadillah N, Naing L. Probable causes and risk factors for positive SARS-CoV-2 test in recovered patients: Evidence from Brunei Darussalam. J Med Virol. 2020;92(11):2847–51.

10. Xiao AT, Tong YX, Zhang S. False negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence. J Med Virol. 2020;92(10):1755–6.

11. O'Reilly GM, Mitchell RD, Rajiv P, Wu J, Brennecke H, Brichko L, et al. Epidemiology and clinical features of emergency department patients with suspected COVID-19: Initial results from the COVID-19 Emergency Department Quality Improvement Project (COVED-1). EMA - Emerg Med Australas. 2020;32(4):638–45.

12. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24(1):4–11.

13. Tangke U. Halaman Sampul. Agrikan J Agribisnis Perikan. 2016;9(2):1–214.

14. Rai P, Kumar BK, Deekshit VK, Karunasagar I, Karunasagar I. Detection technologies and recent developments in the diagnosis of COVID-19 infection. Appl Microbiol Biotechnol. 2021;105(2):441–55.

15. Pertanyaan jawaban terkait COVID-19 untuk publik [Internet]. [cited 2022 Feb 4]. Available from: https://www.who.int/indonesia/news/novel-coronavirus/qa/qa-for-public

16. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and

Prevention. JAMA - J Am Med Assoc. 2020;323(13):1239–42.

17. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol [Internet]. 2019;17(3):181–92. Available from: http://dx.doi.org/10.1038/s41579-018-0118-9

18. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418–23.

19. Xiantian X, Ping C, Jingfang W, Jiannan F, Hui Z, Xuan L, et al. Evolution Of The Novel Coronavirus From The Ongoing Wuhan Outbreak And Modeling Of Its Spike Protein For Risk Of Human Transmission. Sci China Life Sci. 2020;63(3):457–60.

20. Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. *J Microbiol Immunol Infect*. 2021;54(2):159-163. doi:10.1016/j.jmii.2020.03.022

21. Abdel-Moneim AS. Middle East respiratory syndrome coronavirus (MERS-CoV): Evidence and speculations. Arch Virol. 2014;159(7):1575–84.

22. Tragni V, Preziusi F, Laera L, Onofrio A, Mercurio I, Todisco S, et al. Modeling SARS-CoV-2 spike/ACE2 protein–protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context. EPMA J [Internet]. 2022;(0123456789). Available from: https://doi.org/10.1007/s13167-021-00267-w

23. Deng SQ, Peng HJ. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J Clin Med. 2020;9(2).

24. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.

25. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol [Internet]. 2021;19(3):141–54. Available from: http://dx.doi.org/10.1038/s41579-020-00459-7

26. Infeksi Emerging Kementerian Kesehatan RI [Internet]. [cited 2022 Feb 4]. Available from: https://covid19.kemkes.go.id/

27. Kirtipal N, Bharadwaj S, Gu S. Mutation and polymorphisms in genes involved in the infections by covid 19: a review. Infect Genet Evol [Internet]. 2020;85(January):15. Available from: https://doi.org/10.1016/j.meegid.2020.104502

28. Tanonaka K, Marunouchi T. Angiotensin-converting enzyme 2. Folia Pharmacol Jpn. 2016;147(2):120–1.

29. De Wit E, Van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: Recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523–34.

30. Liu L, Wei Q, Alvarez X, Wang H, Du Y, Zhu H, et al. Epithelial Cells Lining Salivary Gland Ducts Are Early Target Cells of Severe Acute Respiratory Syndrome Coronavirus Infection in the Upper Respiratory Tracts of Rhesus Macaques. J Virol. 2011;85(8):4025–30.

31. Chu H, Zhou J, Wong BHY, Li C, Chan JFW, Cheng ZS, et al. Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways. J Infect Dis. 2016;213(6):904–14.

32. Chu H, Zhou J, Wong BH, Li C, Cheng Z, Lin X. molecular basis of coronavirus virulence and vaccine development. 2020;(January).

33. Zhou J, Chu H, Li C, Wong BHY, Cheng ZS, Poon VKM, et al. Active replication of middle east respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: Implications for pathogenesis. J Infect Dis. 2014;209(9):1331–42.

34. Simmons G, Zmora P, Gierer S, Heurich A, Pöhlmann S, Hammond S, et al. Early impact of the COVID-19 pandemic on pediatric cancer care in Latin America. Ann Oncol [Internet]. 2020;268(January):19–21. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550914/pdf/main.pdf

35. Hurst KR, Koetzner CA, Masters PS. Identification of In Vivo-Interacting Domains of the Murine Coronavirus Nucleocapsid Protein. J Virol. 2009;83(14):7221–34.

36. Maier HJ, Bickerton E, Britton P. Coronaviruses: Methods and protocols. Coronaviruses Methods Protoc. 2015;1282(1):1–282.

37. Masters PS. The Molecular Biology of Coronaviruses. Adv Virus Res. 2006;65(January):193–292.

38. Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019;11(1).

39. Sexton NR, Smith EC, Blanc H, Vignuzzi M, Peersen OB, Denison MR. Homology-Based Identification of a Mutation in the Coronavirus RNA-Dependent RNA Polymerase That Confers Resistance to Multiple Mutagens. J Virol. 2016;90(16):7415–28.

40. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.

41. Nanshan Chen 1 , Min Zhou 2 , Xuan Dong 1 , Jieming Qu 2 , Fengyun Gong 3 , Yang Han 4 , Yang Qiu 5 , Jingli Wang 3 , Ying Liu 6 , Yuan Wei 1 , Jia'an Xia 1 , Ting Yu 1 , Xinxin Zhang 7 LZ. IKKE BRUG Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A DescriptNanshan Chen 1 , Min Zhou 2 , Xuan Dong 1 , Jieming Qu 2 , Fengyun Gong 3 , Yang Han 4 , Yang Qiu 5 , Jingli Wang 3 , Ying Li. Lancet. 2020;395(10223):507–13.

42. Channappanavar R, Fett C, Mack M, Eyck PP Ten, Meyerholz DK, Perlman S. Sex-based differences in susceptibility to SARS-CoV infection. J Immunol. 2017;198(10):319–35.

43. Mohamed MS, Moulin TC, Schiöth HB. Sex differences in COVID-19: the role of androgens in disease severity and progression. Endocrine [Internet]. 2021;71(1):3–8. Available from: http://dx.doi.org/10.1007/s12020-020-02536-6

44. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194.

45. Pietrobon AJ, Teixeira FME, Sato MN. I mmunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People. Front Immunol. 2020;11(October):1–18.

46. Kim H, Webster RG, Webby RJ. Influenza Virus: Dealing with a Drifting

and Shifting Pathogen. Viral Immunol. 2018;31(2):174–83.

47. Fung SY, Yuen KS, Ye ZW, Chan CP, Jin DY. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect. 2020;9(1):558–70.

48. Welsh RM, Bahl K, Marshall HD, Urban SL. Type 1 interferons and antiviral CD8 T-Cell responses. PLoS Pathog. 2012;8(1).

49. Sallard E, Lescure F, Yazdanpanah Y, Mentre F, Pei N. The kidney and COVID-19 patients - important considerations. 2020;(January).

50. Kadambari S, Klenerman P, Pollard AJ. Why the elderly appear to be more severely affected by COVID-19: The potential role of immunosenescence and CMV. Rev Med Virol. 2020;30(5):1–5.

51. Lee KA, Ma W, Sikavi DR, Drew DA, Nguyen LH, et al. Cancer and Risk of COVID-19 Through a General Community Survey. Oncologist. 2021;26(1):e182–5.

52. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783.

53. Kang DH, Weaver MT, Park NJ, Smith B, McArdle T, Carpenter J. Significant impairment in immune recovery after cancer treatment. Nurs Res. 2009;58(2):105–14.

54. Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M, et al. planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infection disease. 2020;(January):19–21.

55. Lee LYW, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study. Lancet. 2020;395(10241):1919–26.

56. Yang X, et al. Clinical Course and outcomes of critically ill patients with COVID19 in Wuhan China. Lancet Respir Med. 2020;8(5):475–81.

57. De Almeida-Pititto B, Dualib PM, Zajdenverg L, Dantas JR, De Souza FD, Rodacki M, et al. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: A meta-analysis. Diabetol Metab Syndr [Internet]. 2020;12(1):1–12. Available from: https://doi.org/10.1186/s13098-020-00586-4

58. Iacobellis G, Pitocco D, Tartaglione L, Viti L, Di M, Pontecorvi A, et al. DPP-4 inhibitor and COVID-19 : from. 2020;(January).

59. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;36(7):1–9.

60. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.

61. Lima-Martínez MM, Carrera Boada C, Madera-Silva MD, Marín W, Contreras M. COVID-19 and diabetes: A bidirectional relationship. Clin e Investig en Arterioscler. 2021;33(3):151–7.

62. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein.

bioRxiv. 2020;(January).

63. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science (80-). 2020;367(6483):1260–3.

64. Tajbakhsh A, Gheibi Hayat SM, Taghizadeh H, Akbari A, inabadi M, Savardashtaki A, et al. COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Rev Anti Infect Ther [Internet]. 2021;19(3):345–57. Available from: https://doi.org/10.1080/14787210.2020.1822737

65. South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol - Hear Circ Physiol. 2020;318(5):H1084–90.

66. Tadic M, Cuspidi C, Grassi G, Mancia G. COVID-19 and arterial hypertension: Hypothesis or evidence? J Clin Hypertens. 2020;2(April):1120–6.

67. Susilo A, Rumende CM, Pitoyo CW, Santoso WD, Yulianti M, Herikurniawan H, et al. Coronavirus Disease 2019: Tinjauan Literatur Terkini. J Penyakit Dalam Indones. 2020;7(1):45.

68. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 Patofisiology A: Review. 2020;(January).

69. Cheung KS, Hung IFN, Chan PPY, Lung KC, Tso E, Liu R, et al. Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis. Gastroenterology. 2020;159(1):81–95.

70. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad Med J. 2021;97(1147):312–20.

71. Jayaweera M, Perera H, Gunawardana B, Manatunge J. syndrome coronavirus (MERS-CoV) infection. 2020;188(January):1–18.

72. Duguid JP. Edinburgh Medical Journal November 1945 the numbers and the sites of origin of THE DROPLETS EXPELLED DURING EXPIRATORY ACTIVITIES. 1945;

73. Asadi S, Bouvier N, Wexler AS, Ristenpart WD. The coronavirus pandemic and aerosols: Does COVID-19 transmit via expiratory particles? Aerosol Sci Technol [Internet]. 2020;54(6):635–8. Available from: https://doi.org/10.1080/02786826.2020.1749229

74. Ejazi SA, Ghosh S, Ali N. Antibody detection assays for COVID-19 diagnosis: an early overview. Immunol Cell Biol. 2021;99(1):21–33.

75. wenzhong liu, hualan L. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism. 2020;

76. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–7.

77. Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020;

78. Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated

with COVID-19 disease progression. Crit Rev Clin Lab Sci [Internet]. 2020;0(0):389–99. Available from: https://doi.org/10.1080/10408363.2020.1770685

79. Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J Med Virol. 2020;92(7):856–62.

80. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med. 2020;382(13):1199–207.

81 Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk Factors Associated with Mortality among Patients with COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern Med. 2020;180(10):1345–55.

83. Zhou C, Gao C, Xie Y, Xu M. COVID-19 with spontaneous pneumomediastinum. Lancet Infect Dis. 2020;20(4):510.

84. Zeng JH, Liu YX, Yuan J, Wang FX, Wu WB, Li JX, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection [Internet]. 2020;48(5):773–7. Available from: https://doi.org/10.1007/s15010-020-01424-5

85. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol [Internet]. 2020;17(5):259–60. Available from: http://dx.doi.org/10.1038/s41569-020-0360-5

86. Ron Gilat, M.D., Eric D. Haunschild B.S., Tracy Tauro B.S. B.A., Brian J. Cole M.D. MB. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-. Ann Oncol. 2020;(January):19–21.

87. Manssor B, Patel J, Parekh D. Since January 2020 SARS-CoV-2: Is the liver merely a bystander to severe disease? . The COVID-19 resource centre is hosted on Elsevier Connect , the company ' s public news and information. 2020;(January):19–21.

88. Ji Y, Ma Z, Peppelenbosch MP, Pan Q. Potential association between COVID-19 mortality and health-care resource availability. Lancet Glob Heal. 2020;8(4):e480.

89. Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 .. 2020;(January).

90. Bounds EJ, Kok SJ. D Dimer. StatPearls [Internet]. 2021 Jul 14 [cited 2022 Feb 6]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK431064/

91. Nehring SM, Goyal A, Bansal P, Patel BC. C Reactive Protein. StatPearls [Internet]. 2021 Dec 28 [cited 2022 Feb 6];65(5):237–44. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441843/

92. Hakim LN. Urgensi Revisi Undang-Undang tentang Kesejahteraan Lanjut Usia. Aspir J Masal Sos. 2020;11(1):43–55.

93. Yu H, Qin C, Chen M, Wang W, Tian D. D-dimer level is associated with the severity of COVID-19. 2020;(January).

94. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health [Internet]. 2020;13(12):1833–9. Available from:

https://doi.org/10.1016/j.jiph.2020.07.014

95. Khaerunnisa R, Aula Rumana N, Yulia N, Fannya P. Gambaran Karakteristik Pasien Covid-19 di Rumah Sakit Mekar Sari Bekasi Tahun 2020-2021. J Manaj Inf Kesehat Indones. 2022;10(1):64–72.

96. Widjaja JT, Kwee L, Giantara AK, Subagiyo HA, Edwin C, Putri RL. Karakteristik Pasien COVID-19 Rawat Inap di RS Immanuel Bandung, Indonesia Characteristics of Inpatient Covid-19 Patients at Immanuel Hospital Bandung, Indonesia. J Med Heal Karakteristik Pasien COVID-19 Rawat. 2021;3(2):164–75 Mahardhika GS, Tedjamartono TD, Buwono PW. High D-dimer and CRP

97. Destylya, Dyana. Karakteristik Pasien Covid-19 di Rumah Sakit Umum Pusat Haji Adam Malik Medan Sumatera Utara. 2020

98. Atna Permana, Cut Ervinar Yari, Alaika Kurnia Aditya. Gambaran D-Dimer Dan Limfosit Pada Pasien Terkonfirmasi Covid-19 Di Rs Haji Jakarta Tahun 2020-2021. jurnal Thamrin,2021.

99. Mahardhika GS, Tedjamartono TD, Buwono PW. High D-dimer and CRP Levels in an Asymptomatic COVID-19 Patient: A Case Report and Brief Literature Review. Semin Nas Ris Kedokt [Internet]. 2021;2(1):2021.

100. Hunt BJ, Levi M. Re The source of elevated plasma D-dimer levels in COVID-19 infection. Br J Haematol. 2020;190(3):e133–4.

101. (Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int J Hematol. 2021 Jan;113(1):45-57. doi: 10.1007/s12185-020-03029-y. Epub 2020 Nov 7. PMID: 33161508; PMCID: PMC7648664.)

102. Naymagon L, Zubizarreta N, Feld J, Gerwen M Van, Alsen M, Thibaud S, et al. Admission D-dimer levels , D-dimer trends , and outcomes in COVID-19. 2020;(January).

103 Kario K, Morisawa Y, Sukonthasarn A, Turana Y, Chia YC, Park S, et al. COVID-19 and hypertension—evidence and practical management: Guidance from the HOPE Asia Network. J Clin Hypertens. 2020;22(7):1109–19.

104. Lima-Martínez MM, Carrera Boada C, Madera-Silva MD, Marín W, Contreras M. COVID-19 and diabetes: A bidirectional relationship. Clin e Investig en Arterioscler. 2021;33(3):151–7.

105. An C, Lim H, Kim DW, Chang JH, Choi YJ, Kim SW. Machine learning prediction for mortality of patients diagnosed with COVID-19: a nationwide Korean cohort study. Sci Rep [Internet]. 2020;10(1):1–11. Available from: https://doi.org/10.1038/s41598-020-75767-2

106. Woskie LR, Hennessy J, Espinosa V, Tsai TC, Vispute S, Jacobson BH, et al. Early social distancing policies in Europe, changes in mobility & COVID-19 case trajectories: Insights from Spring 2020. PLoS One [Internet]. 2021;16(6 June):1–12. Available from: http://dx.doi.org/10.1371/journal.pone.0253071

107. Armstrong D. The COVID-19 pandemic and cause of death. Sociol Heal Illn. 2021;43(7):1614–26.

108. Surendra H, Elyazar I, Djaafara B, Ekawati L, Saraswati K, Adrian V, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. Lancet. 2021;9:100108.

109. (Surendra H, Elyazar I, Djaafara B, Ekawati L, Saraswati K, Adrian V, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. Lancet. 2021;9:100108)

110. Salian VS, Wright JA, Vedell PT, Nair S, Li C, Kandimalla M, et al. COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies. Mol Pharm. 2021;18(3):754–71.

111. Fahmia R, Helda H, Nursari AY. Lama Rawat Inap Pasien Terkonfirmasi COVID-19 di Rumah Sakit Universitas Indonesia dan Faktor yang Mempengaruhinya. J Epidemiol Kesehat Indones. 2022;6(1):1–12.